A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Financial Summary
| Share Statistics | VTRLY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,302.5 | $292.6 | 48% |
|
| Shares Out (Mil) | 14.0 | 54.4 | 25% |
|
| Institutional Ownership | 99.9% | 93.2% | 96% |
|
| Float (Mil) | 73.7 | 40.2 | 55% |
|
| Beta | 1.72 | 0.94 | 88% |
|
| Avg Daily Volume (000s) | 0 | 544 | 0% |
|
| Price Change (52-week) |
na | 59.7% | na |
|
| Growth | VTRLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.7% | 13.6% | 81% |
|
| Net Income (5yr) | (77.4%) | (10.1%) | 3% |
|
| EPS (5yr) | (70.6%) | 16.0% | 2 |
|
| Dividends (5yr) | 4.1% | 0.0% | 57% |
|
| Cash Flow (5yr) | (23.9%) | (15.6%) | 27% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VTRLY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $350 | $37 | 37% |
|
| Net Income (TTM) (Mil) | ($514) | ($43) | 3% |
|
| EPS (TTM) | ($3.797) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | $75 | ($31) | 49% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $2 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $161 | $4 | 48% |
|
| Enterprise Value (Q1) (Mil) | $1,319 | $164 | 44% |
|
| Valuation | VTRLY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VTRLY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 59.2% | 64.2% | 72% |
|
| Net Margin | (147.0%) | (75.9%) | 6% |
|
| ROA | (35.0%) | (47.5%) | 15% |
|
| ROE | (46.0%) | (55.0%) | 16% |
|
| Liabilities to Assets | 28.0% | 29.6% | 20% |
|
| F-Score | na | 3 | na |
|
Vitrolife AB (publ) did not pass any screens on 8/21/2026.
